Literature DB >> 10773001

Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro.

K Venkatakrishnan1, L L von Moltke, R S Obach, D J Greenblatt.   

Abstract

The effect of binding of amitriptyline to human liver microsomes and to microsomes from human B-lymphoblastoid cells on the estimation of enzyme kinetic parameters describing N-demethylation to nortriptyline was investigated using a combination of microsomal binding and in vitro enzyme kinetic studies. Quantitative binding in both matrices increased with higher microsomal protein concentrations (free fractions 0.88-0.32 at 100-500 microg protein/ml in human liver microsomes and 0.82-0.26 at 250-1000 microg protein/ml in microsomes from B-lymphoblastoid cells) and was independent of amitriptyline concentration over a concentration range of 0.2 to 200 microM. Addition of heat-inactivated microsomal protein (50-450 microg/ml) to native human liver microsomes (50 microg/ml) reduced the amitriptyline N-demethylation rate in a protein concentration dependent manner. This effect was greater at lower substrate concentrations and was overcome by saturating concentrations of substrate, thereby decreasing the apparent affinities of the high- and low-affinity components of the N-demethylation process, with minimal effect on the net V(max). Addition of metabolically inactive microsomes from untransfected human lymphoblastoid cells (750 microg/ml) to CYP2C19 (250 microg/ml protein) increased the apparent K(m) value for amitriptyline N-demethylation by 3.5-fold and increased the uncompetitive substrate inhibition constant (K(s)) by 2.2-fold, making substrate inhibition essentially undetectable. A similar effect was seen with CYP3A4, with a 1.8-fold increase in the S(50) (substrate concentration at which half-maximal velocity of a Hill enzyme is achieved). Microsomal binding did not alter the V(max) of either CYP isoform to any appreciable extent. These findings emphasize the importance of incorporating microsomal binding in the estimation of enzyme kinetic parameters in vitro and making appropriate corrections for unbound drug concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773001

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

Authors:  Daniel R McMasters; Rhonda A Torres; Susan J Crathern; Deborah L Dooney; Robert B Nachbar; Robert P Sheridan; Kenneth R Korzekwa
Journal:  J Med Chem       Date:  2007-06-09       Impact factor: 7.446

2.  Drug Distribution. Part 1. Models to Predict Membrane Partitioning.

Authors:  Swati Nagar; Ken Korzekwa
Journal:  Pharm Res       Date:  2016-12-15       Impact factor: 4.200

3.  Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.

Authors:  Timothy J Taylor; Kelly Diringer; Tanya Russell; Karthik Venkatakrishnan; Keith Wilner; Penelope H Crownover; Lisa J Benincosa; Megan A Gibbs
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Authors:  Collen M Masimirembwa; Ulf Bredberg; Tommy B Andersson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions.

Authors:  Avanthika Venkatachalam; Abhinav Parashar; Kelath Murali Manoj
Journal:  In Silico Pharmacol       Date:  2016-02-19

Review 8.  Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

Authors:  M Teresa Donato; José V Castell
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.